Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01464905 is registered in ClinicalTrials.gov with Nuron Biotech Inc. as lead sponsor.

NCT NCT01464905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01464905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Nuron Biotech Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2011
Completion date
December 31, 2014
Enrollment
500 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis